734 related articles for article (PubMed ID: 28111133)
1. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
2. A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations.
Abamor ES; Allahverdiyev AM
Exp Parasitol; 2016 Jul; 166():150-63. PubMed ID: 27109311
[TBL] [Abstract][Full Text] [Related]
3. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
4. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.
Shokri A; Sharifi I; Khamesipour A; Nakhaee N; Fasihi Harandi M; Nosratabadi J; Hakimi Parizi M; Barati M
Parasitol Res; 2012 Mar; 110(3):1113-7. PubMed ID: 21847598
[TBL] [Abstract][Full Text] [Related]
5. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
[TBL] [Abstract][Full Text] [Related]
6. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
[TBL] [Abstract][Full Text] [Related]
7. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
8. Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro.
Allahverdiyev AM; Abamor ES; Bagirova M; Baydar SY; Ates SC; Kaya F; Kaya C; Rafailovich M
Exp Parasitol; 2013 Sep; 135(1):55-63. PubMed ID: 23792003
[TBL] [Abstract][Full Text] [Related]
9. Antileishmanial Activity of 2-Methoxy-4H-spiro-[naphthalene-1,2'-oxiran]-4-one (Epoxymethoxy-lawsone): A Promising New Drug Candidate for Leishmaniasis Treatment.
Oliveira LFG; Souza-Silva F; de Castro Côrtes LM; Cysne-Finkelstein L; de Souza Pereira MC; de Oliveira Junior FO; Pinho RT; Corte Real S; Bourguignon SC; Ferreira VF; Alves CR
Molecules; 2018 Apr; 23(4):. PubMed ID: 29642584
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
11. In vitro antileishmanial activity of fisetin flavonoid via inhibition of glutathione biosynthesis and arginase activity in Leishmania infantum.
Adinehbeigi K; Razi Jalali MH; Shahriari A; Bahrami S
Pathog Glob Health; 2017 Jun; 111(4):176-185. PubMed ID: 28385129
[TBL] [Abstract][Full Text] [Related]
12. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D
Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518
[TBL] [Abstract][Full Text] [Related]
13. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
14. Study of the
Azadi R; Alipour-Talesh G; Yazdanpanah MJ; Alavizadeh SH; Maleki M; Banihashemi M; Jaafari MR
J Vector Borne Dis; 2020; 57(1):78-84. PubMed ID: 33818460
[TBL] [Abstract][Full Text] [Related]
15. Investigation of antileshmanial activities of Cuminum cyminum based green silver nanoparticles on L. tropica promastigotes and amastigotes in vitro.
Bagirova M; Dinparvar S; Allahverdiyev AM; Unal K; Abamor ES; Novruzova M
Acta Trop; 2020 Aug; 208():105498. PubMed ID: 32428676
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antileishmanial activity and cytotoxicity of the extracts of Berberis vulgaris and Nigella sativa against Leishmania tropica.
Mahmoudvand H; Sharififar F; Rahmat MS; Tavakoli R; Dezaki ES; Jahanbakhsh S; Sharifi I
J Vector Borne Dis; 2014 Dec; 51(4):294-9. PubMed ID: 25540961
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
18. Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions.
Carrió J; de Colmenares M; Riera C; Gállego M; Arboix M; Portús M
Exp Parasitol; 2000 Jul; 95(3):209-14. PubMed ID: 10964649
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of total phenolic fraction derived from extra virgin olive oil for its antileishmanial activity.
Koutsoni OS; Karampetsou K; Kyriazis ID; Stathopoulos P; Aligiannis N; Halabalaki M; Skaltsounis LA; Dotsika E
Phytomedicine; 2018 Aug; 47():143-150. PubMed ID: 30166099
[TBL] [Abstract][Full Text] [Related]
20. In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
Gutiérrez J; Vallejo B; Barbosa H; Pinzón J; Delgado G
Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):321-8. PubMed ID: 23473403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
